Sequential high-dose cytarabine plus idarubicin improves remission rate and survival duration in adult acute myelogenous leukemia (AML): Randomized trial of the Northern Italy leukemia group (NILG)

This article has no abstract
Epistemonikos ID: 403af44cf3209da038988622ec004ec3b00b9a93
First added on: Feb 08, 2025